SGLT2 inhibitors are the only class of anti-diabetic drugs proven to be beneficial in the management of patients with established HF, either chronic HF with reduced, mildly reduced, or preserved ejection fraction, or acute decompensated HF. Here, SLC5A2 is linked to hydrops fetalis.